Mustang ties the knot with Fred Hutch on next-gen CAR-T for lymphoma – Endpoints News
Endpoints News |
Mustang ties the knot with Fred Hutch on next-gen CAR–T for lymphoma
Endpoints News The way these CAR-T drugs work is by taking immune T cells then reengineering them to transform them into cancer cell-targeting therapies. Novartis just scored the pioneering OK, with Kite close behind and a slew of biotechs hoping to make their mark … Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies Fred Hutch licenses new immunotherapy treatment to Mustang Bio, preps pre-clinical trials in Seattle |
